医学
射血分数
安慰剂
心脏病学
内科学
四分位间距
心肌梗塞
不利影响
缺血性心肌病
心力衰竭
心功能曲线
疤痕
外科
病理
替代医学
作者
Philippe Menasché,Ottavio Alfieri,Stefan P. Janssens,William John McKenna,Hermann C. Reichenspurner,Ludovic Trinquart,Jean‐Thomas Vilquin,Jean‐Pierre Marolleau,Barbara Seymour,Jérôme Larghero,Stephen L. Lake,Gilles Châtellier,Scott David Solomon,Michel Desnos,Albert Alain Hagège
出处
期刊:Circulation
[Lippincott Williams & Wilkins]
日期:2008-02-19
卷期号:117 (9): 1189-1200
被引量:1072
标识
DOI:10.1161/circulationaha.107.734103
摘要
BACKGROUND: Phase I clinical studies have demonstrated the feasibility of implanting autologous skeletal myoblasts in postinfarction scars. However, they have failed to determine whether this procedure was functionally effective and arrhythmogenic. METHODS AND RESULTS: This multicenter, randomized, placebo-controlled, double-blind study included patients with left ventricular (LV) dysfunction (ejection fraction < or = 35%), myocardial infarction, and indication for coronary surgery. Each patient received either cells grown from a skeletal muscle biopsy or a placebo solution injected in and around the scar. All patients received an implantable cardioverter-defibrillator. The primary efficacy end points were the 6-month changes in global and regional LV function assessed by echocardiography. The safety end points comprised a composite index of major cardiac adverse events and ventricular arrhythmias. Ninety-seven patients received myoblasts (400 or 800 million; n=33 and n=34, respectively) or the placebo (n=30). Myoblast transfer did not improve regional or global LV function beyond that seen in control patients. The absolute change in ejection fraction (median [interquartile range]) between 6 months and baseline was 4.4% (0.2; 7.3), 3.4% (-0.3; 12.4), and 5.2% (-4.4; 11.0) in the placebo, low-dose, and high-dose groups, respectively (P=0.95). However, the high-dose cell group demonstrated a significant decrease in LV volumes compared with the placebo group. Despite a higher number of arrhythmic events in the myoblast-treated patients, the 6-month rates of major cardiac adverse events and of ventricular arrhythmias did not differ significantly between the pooled treatment and placebo groups. CONCLUSIONS: Myoblast injections combined with coronary surgery in patients with depressed LV function failed to improve echocardiographic heart function. The increased number of early postoperative arrhythmic events after myoblast transplantation, as well as the capability of high-dose injections to revert LV remodeling, warrants further investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI